Followers | 1082 |
Posts | 80397 |
Boards Moderated | 9 |
Alias Born | 03/10/2009 |
Thursday, June 17, 2021 1:48:55 PM
05/07/2021 | 07:02am EDT
share with twitter
share with LinkedIn
share with facebook
(MT Newswires) -- Orphazyme A/S (ORPH) said Friday its phase 3 trial of arimoclomol to treat amyotrophic lateral sclerosis did not meet its primary or secondary endpoints.
The trial's primary endpoint was to evaluate the efficacy of chronic treatment with arimoclomol compared with placebo while the secondary endpoint included survival, functional improvement and slow vital capacity.
Topline data will be presented at the upcoming virtual European Network to Cure ALS meeting. No important safety signals were observed, the company said.
Shares fell nearly 30% in premarket trading
Price: 6.00, Change: -2.56, Percent Change: -29.91
© MT Newswires 2021
STOP & VISIT MY BOARD AT: HOTTEST PENNY STOCK PICKS
http://investorshub.advfn.com/boards/board.aspx?board_id=19627
My posts are NOT a buy/sell recommendation, Do your Own DD, before you buy any stock - I reserve the right to buy/sell any stock
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM